Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsChild and adolescent psychiatry — early-onset psychosis

Psych MEQs / SAQs · Child and adolescent psychiatry — early-onset psychosis

Early-onset psychosis — CAP assessment to clozapine threshold (MEQ)

FRANZCP-style MEQ on early-onset psychosis: age definitions, CAP differentials, organic/baseline work-up, start-low antipsychotic, family/school modules, clozapine threshold.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 14-year-old is brought by parents after 4 months of school failure and 10 weeks of believing classmates track him via his phone. He hears a third-person commentary. He has a prior autism spectrum diagnosis and smokes high-THC cannabis most weekends. He is afebrile and alert; observations and bedside glucose are normal. Insight is partial. Parents ask if this is 'just autism' and whether medication will ruin his metabolism. (i) Define EOP vs VEOP/COS and calculate the clinical importance of DUP here. (ii) Outline the CAP differential (including autism, trauma, substance, organic) with discriminators. (iii) List baseline investigations before antipsychotics and when you escalate organic tests. (iv) Give a named first-line oral antipsychotic with a youth start-low plan, monitoring and trial length. (v) Describe multi-element youth care (family, school, substance) and the clozapine threshold if two adequate trials fail. (20 marks)

Model answer

Reveal model answer

(i) Definitions and DUP. Early-onset psychosis is frank psychotic disorder with onset before age 18; very-early-onset / childhood-onset schizophrenia is conventionally onset before 13. This 14-year-old sits in the EOP band (not VEOP). Working label: first-episode schizophrenia-spectrum psychosis with dual substance and autism comorbidity — provisional until duration and course clarify. DUP is at least about 10 weeks of frank psychosis (phone tracking, commentary); longer if school failure counts toward untreated illness definitions. Longer DUP associates with poorer outcomes — treatment should start now to stop the clock.[1][5]

(ii) Differential with discriminators. Not "just autism": lifelong ASD may explain baseline social-communication style, but new fixed delusions, commentary hallucinations and functional collapse indicate a psychotic episode needing dual formulation. Trauma/PTSD: trauma timeline, flashbacks, dissociation. Substance: weekend high-THC may contribute but does not exclude primary illness; dual formulation. Organic: currently no fever/seizure/fluctuating attention, but keep encephalitis pathway if red flags emerge. Also consider affective psychosis and OCD with poor insight.[1]

(iii) Investigations. Baseline before antipsychotic: weight/BMI (growth chart), BP, glucose or HbA1c, lipids, FBC, U&E, LFT, thyroid as indicated, ECG QTc, pregnancy test if applicable, substance history; urine drug screen supports never excludes. Escalate neuroimaging/EEG/LP/autoimmune panel if fever, seizure, focal neurology, rapid cognitive decline, catatonia or very atypical course.[1][4]

(iv) Antipsychotic plan. Example: aripiprazole started low (youth-appropriate titration toward an effective range such as around 10 mg daily depending on age/weight and product guidance), after baselines, with education about akathisia. Trial about 4–6 weeks at therapeutic dose with adherence support. Alternatives guided by TEOSS-style evidence and side-effect profiles (risperidone prolactin/EPS; olanzapine high metabolic burden — monitor hard). First-time SGA exposure in youth drives early cardiometabolic risk — weight every visit initially.[2][4]

(v) Multi-element care and clozapine threshold. Youth EIS/CAMHS package: low-dose medication, family psychoeducation, school liaison plan, cannabis motivational work, case management, psychological therapy access, safety plan. Cannabis cessation is secondary prevention. If two adequate adherent trials fail, escalate toward clozapine (Kumra evidence in refractory early-onset schizophrenia) rather than endless non-clozapine cycling.[1][3][6]

Common errors

  • Calling everything "just autism" or "just cannabis" without dual formulation.
  • Starting antipsychotics without metabolic/ECG baseline.
  • Omitting family and school modules.
  • High first-dose polypharmacy "to be strong."
  • Never naming clozapine after two adequate failures.
  • Inventing Mental Health Act section numbers for the wrong jurisdiction. [1]

Examiner notes

Full marks require age definitions, DUP reasoning, CAP discriminators (autism/trauma/substance/organic), baseline checklist, named drug with start-low plan and monitoring, multi-element family/school care, and clozapine threshold with Kumra-level evidence. Vague "start an atypical and review" fails. [1][2][3]

References

  1. [1]McClellan J, Stock S, AACAP Committee on Quality Issues Practice parameter for the assessment and treatment of children and adolescents with schizophrenia J Am Acad Child Adolesc Psychiatry, 2013.PMID 23972700
  2. [2]Sikich L, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the TEOSS study Am J Psychiatry, 2008.PMID 18794207
  3. [3]Kumra S, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison Biol Psychiatry, 2008.PMID 17651705
  4. [4]Correll CU, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA, 2009.PMID 19861668
  5. [5]Marshall M, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review Arch Gen Psychiatry, 2005.PMID 16143729
  6. [6]Schoeler T, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study Lancet Psychiatry, 2016.PMID 27567467